BACKGROUND: Urethrocutaneous fistulae (UCFs) represent one of the most frequent causes of morbidity after urethroplasty. @entity2650 can be repaired using different surgical techniques, but-regardless of technique-the incidence of UCF ranges between 10% and 40%. Surgical repair of UCF remains the treatment of choice, even if some @entity1 need further surgery because of recurrences. Cyanoacrylates have been used as skin suture substitutes, and some evidence suggests a beneficial effect when these adhesives are used as an adjuvant in the management of UCF. Here we describe the results of management of UCF using @entity21079 ( @entity25053 ) compared with surgical repair. METHODS: A randomized clinical trial conducted from January 2008 to December 2012 included 42 @entity1 with UCF complications after urethroplasty for @entity2650 . Twenty-one @entity1 were assigned to receive OCA as ambulatory @entity1 and 21 were treated surgically. The main outcome variable was closure of the UCF. The estimated costs of both treatments were also calculated, as were absolute risk reduction (ARR), relative risk reduction (RRR) and number needed to treat (NNT) to prevent a surgical intervention. RESULTS: The mean numbers of UCF were 1.3 in the OCA group (n = 28) and 1.1 in the surgical group (n = 25) with no statistically significant difference. The external orifices measured were 2.96    1.0 mm and 3.8    0.89 mm, respectively ( @entity7031 ). Sixty per cent of the UCFs treated with @entity3080 were completely closed and 68% of the surgical group healed completely ( @entity7031 ). More than one reoperation to improve complications was needed in the surgical group (3.5    1.2). The clinical significance of the therapeutic usefulness of OCA was demonstrated by an ARR of 0.08, RRR of 0.25 and NNT of 12 to avoid further surgical treatment. The total costs of adhesive applications and reoperations were  US 14,809.00 and  US 158,538.50, respectively. CONCLUSIONS: The results showed a similar success rate for both treatments. However, sealant use should be considered before surgical treatment because this is a simple outpatient procedure with a reasonable success rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02115191. Date: April 13, 2014.

XXXX versus reintervention for closure of urethrocutaneous fistulae after urethroplasty for @entity2650 : a randomized controlled trial.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity2650 :: ('MESH:D007021', 'Disease') :: ['Hypospadias', 'hypospadias'] @entity3080 :: ('MESH:D003487', 'Chemical') :: ['cyanoacrylate'] @entity21079 :: ('MESH:C100832', 'Chemical') :: ['2-octyl cyanoacrylate'] @entity7031 :: ('MESH:D056770', 'Disease') :: ['NS'] @entity25053 :: ('CHEBI:31344', 'Chemical') :: ['OCA']
@entity21079 :: (MESH:C100832,Chemical) :: ['2-octyl cyanoacrylate']
